

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Naloxegol for treating opioid-induced constipation

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final Appraisal Determination

1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

An issue raised by a consultee was that any recommendations specifying an upper age limit for receiving treatment with naloxegol may discriminate against elderly people. The manufacturer clarified that it was not expecting that the marketing authorisation would include an upper age limit. A consultee also raised that the Committee should be aware when making its preliminary recommendations that if these recommendations specify a required prior length of treatment with prior laxative treatment, this treatment period could have an impact on access to naloxegol treatment for people with cancer pain and opioid-induced constipation who may have a short life expectancy.

The Committee recommended naloxegol within its marketing authorisation for treating opioid-induced constipation that has not adequately responded to laxatives. People who are older and people with cancer pain and opioid-induced constipation who may have a short life expectancy would be able to receive naloxegol in line with its marketing authorisation. Therefore, these potential equality issues are not considered to be equality issues for this appraisal topic and are not relevant to the Committee's recommendations. No changes or adjustments to the Committee's recommendations are required.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these?

No other potential equality issues have been raised.

3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?

No other potential equality issues have been identified by the Committee.

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No.

7. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?
Not applicable

Approved by Programme Director (name): ...Meindert Boysen

Date: 19 May 2015